2 Potentially High-Reward Growth Stocks to Buy Right Now

Group 1: Industry Overview - Growth stocks have been outperforming value and dividend stocks since 2008, with the gap widening post-pandemic [1] - Biotechnology has been one of the best-performing industries until interest rates changed in 2022, with many top growth stocks currently trading at low valuations [2] Group 2: Avidity Biosciences - Avidity Biosciences is pioneering a new approach to RNA therapeutics through antibody-oligonucleotide conjugates (AOCs), combining RNA therapeutic precision with monoclonal antibody specificity [3] - The lead candidate, Del-desiran (AOC 1001), targets myotonic dystrophy type 1, affecting around 40,000 individuals in the U.S., with a pivotal trial expected to launch soon [4] - Major clinical updates from the trial are anticipated around mid-2025, with successful outcomes potentially unlocking significant shareholder value [5] - The company has a cash runway extending into 2026, minimizing short-term dilution risk, though clinical setbacks could negatively impact share prices [6] Group 3: Larimar Therapeutics - Larimar Therapeutics is developing a protein replacement therapy, nomlabofusp, for Friedreich's ataxia (FA), a rare genetic disease, highlighting the high stakes in this treatment area [7] - The stock has increased over 55% this year due to the FDA lifting a partial clinical hold, positive trial updates, and a successful capital raise extending its cash runway into 2026 [8] - Larimar's market capitalization of $459 million may not reflect its value proposition, given the $2 billion-plus market opportunity for FA treatments, with the unique profile of nomlabofusp potentially allowing for significant market share capture [9] - The company's future is highly dependent on the success of its FA therapy, making it a high-risk but potentially high-reward investment [10]